| Document |
Document Title |
|
WO/2006/048152A2 |
The invention is concerned with novel dicarboxamide derivatives of formula (I) wherein A, B, RC, D and E are as defined in the description and in the claims, as well 5as physiologically acceptable salts thereof. These compounds inhibit t...
|
|
WO/2006/047479A2 |
The invention is directed to compounds of Formula (I) wherein A, R1, R2, R3, R4, X, and W are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyr...
|
|
WO/2006/047503A2 |
The invention relates to compounds of Formula (I) wherein A, R1, R2, X, Y and W are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kina...
|
|
WO2005123706A9 |
This invention relates to crystalline polymorphs of (3S)-N-hydroxy-4-({4-[(4-hydroxy-2-butynyl)oxy]phenyl}sulfon
yl)-2,2-dimethyl-3-thiomorpholine carboxamide, and preparation and uses thereof.
|
|
WO/2006/042097A1 |
A process for producing a phenothiazinium compound comprising the step of: reacting phenothiazine, in the presence of a halogen, with at least one 5 amine selected from the group consisting of: wherein Z is CH2, O, S, SO2, NH, NCH3, NC2H...
|
|
WO/2006/037775A1 |
Enantiopure heterocyclic compound Enantiopure heterocyclic compound of formula (I) in which J is chosen from C, N, O and S; Z is H or a group for protecting the amino functional group, R3 denotes H or an organic residue, m is 0, 1 or 2 a...
|
|
WO/2006/032847A1 |
A phenothiazinium compound, compositions and medicaments for use in promoting wound healing and a method for promoting wound healing or cosmetic use by applying or administering a phenothiazinium compound to a wound site or the skin, and...
|
|
WO/2006/032879A2 |
This invention pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesizing and purifying certain 3,7 diamino-phenothiazin-5-ium compounds (referred to herein as 'diaminophenoth...
|
|
WO/2006/031134A1 |
The invention relates to compounds of formula (I) or formula (II) which have anti-inflammatory activity and comprise a new class of NSAIDs. The compounds are therefore useful for treating inflammatory diseases or disorders. The invention...
|
|
WO/2006/021282A1 |
The invention relates to novel compounds containing at least one multiple bond that is excited by irradiation with polarised light and thus produces an anisotropy in films containing said compounds or amplifies an already existing anisot...
|
|
WO/2006/023381A1 |
This invention relates to treating inflammatory and immune diseases with certain pyrimidinone compounds that bind to CXCR3 receptors. The pyrimidinone compounds are covered by the formula (I) shown below. Each variable is defined in the ...
|
|
WO/2006/014405A2 |
Various sulfonamide-based compounds are able to selectively inhibit the Src family of tyrosine kinases. These compounds are useful in the treatment of various diseases including hyperproliferative diseases, hematologic diseases, osteopor...
|
|
WO/2006/014207A1 |
Compounds comprising formula (I): or a pharmaceutically acceptable salt or a produg thereof is disclosed herein. A, X, J, E, and Z are as described herein. These compounds are useful for treating glaucoma or ocular hypertension.
|
|
WO/2006/005185A1 |
Inhibitors of indoleamine 2,3-dioxygenase (IDO) are provided as are pharmaceutical compositions containing such inhibitors as well as the use of such inhibitors and compositions for the treatment of a condition in a mammalian subject cha...
|
|
WO/2006/002441A1 |
Novel phenothiazine derivatives and their use in the treatment of diabetes mellitus (type I and type II), and as an ovulation inhibitor (contraceptive), cancer chemotherapeutic and/or prophylactic agent, anti-obesity drug (body weight re...
|
|
WO/2005/123705A1 |
Processes for using a compound of formula (III). to make compounds of formulae (I) and (II) and processes for making the compound of formula III, where R1-5 and J are as defined herein.
|
|
WO/2005/123933A1 |
A process for preparing the compound of formula (II) by reacting the compound of formula (I) with an enzyme that can hydrolyze the ester bond: formula (I) and (II) where * indicates a chiral center, R1 and R2 each independently represent...
|
|
WO/2005/121073A1 |
The present invention relates to a benzamide derivative comprising a head, spacer and cap group wherein the spacer includes a benzene ring substituted with an additional spacer and wherein the additional spacer is an unsaturated group.
|
|
WO/2005/117847A2 |
The invention features compounds of 'formula (I) and their use in preparing 'medicaments for treating a patient having a cancer or other neoplasm. R' R9 R8 R N R7
|
|
WO/2005/113526A2 |
Metabolites of 4-(3,4-dichloro-phenyl)-2-[2-(4methyl-piperazin-1-yl)-benzyl
idene]-thiomorpholin-3-one, and use of same. Formula (I).
|
|
WO/2005/113525A1 |
The present invention relates to novel ketone compounds having Asp2 (β-secretase, BACE1 or Memapsin 2) inhibitory activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases c...
|
|
WO/2005/113524A1 |
The invention refers to compounds according to formula (I), wherein Rl is independently in position 2', 3', or in both positions of the A ring and is hydroxyl, linear or branched -0-alkyl, wherein the alkyl group has 1-12 carbon atoms, p...
|
|
WO/2005/110422A2 |
A method of treating or preventing of a disease or condition associated with an increased level of isoforms of amyloid ß peptides (Aß) and/or with a changed ratio of levels of A isoforms and/or with the formation of plaques containing ...
|
|
WO/2005/102989A1 |
The present invention provides compounds for treating or preventing an HIV infection, or treating AIDS or ARC comprising administering a compound according to formula (I) where Ar, R1-R5, R11c and X1 are as defined herein.
|
|
WO/2005/100333A1 |
Processes are disclosed for the synthesis of Delta-9 tetrahydrocannabinol which result in an improved Y-THC/Y-THC ratio, and intermediates are disclosed that may be used in the synthesis of Delta-9 tetrahydrocannabinol such that improved...
|
|
WO/2005/100318A1 |
The present invention relates to alkanoic acids and their derivatives, which have PPAR agonist activity, and hence can be used as antidiabetic compounds. Compounds disclosed herein can be used for the treatment of diabetes and diabetes-a...
|
|
WO2005030794B1 |
The present invention provides compounds having formula (I): and additionally provides methods for the synthesis thereof and methods for the use thereof in the treatment of cancer, wherein R1-R7, X1, X2, R, Q, and n are as defined herein.
|
|
WO/2005/097761A1 |
The present invention is directed to phenylaminopropanol derivatives of formula I: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of con...
|
|
WO/2005/092099A1 |
Bicyclic uracils and related compounds are inhibitors of HIV integrase and inhibitors of HIV replication. In one embodiment, the compounds are of Formula (I) wherein a, b, Y, R1, R2, R3 and R4 are defined herein. The compounds are useful...
|
|
WO/2005/092392A2 |
Novel chemical conjugates of psychotropic drugs and organic acids, uses thereof in the treatment of CNS and/or proliferative disorders and diseases and as chemosensitizing agents, and their syntheses are disclosed. The organic acids are ...
|
|
WO/2005/092872A1 |
Benzothiazine compounds of the general formula (I) and pharmaceutically acceptable salts or esters thereof are peptide deformylase inhibitors useful in the treatment or prevention of infections and other diseases in which peptide deformy...
|
|
WO/2005/087754A1 |
The present invention relates to morpholine and thiomorpholine derivatives of the general formula I or pharmaceutically acceptable salts thereof and their use.
|
|
WO/2005/082882A1 |
The invention relates to compounds of general formula (I), where R1 and R2 are independently selected from a hydrogen atom, a branched or straight chain alkyl with 1 to 6 carbon atoms, a fluoroalkyl group with 1 to 6 carbon atoms and 3 t...
|
|
WO/2005/082872A1 |
A medicine which contains as an active ingredient a benzothiazin-3-one compound represented by the formula (1): (wherein n is 3 or 4; R represents ethyl or hydrogen; and R1 represents halogeno, alkoxy, haloalkyl, or haloalkoxy) or a phar...
|
|
WO/2005/063692A1 |
The invention relates to (hetero)cyclyl carboxanilides of general formula (I), wherein n represents 0, 1, 2, 3, or 4, m represents 1, 2, or 3, Y represents oxygen or sulfur, A represents optionally substituted phenyl or an at least monou...
|
|
WO/2005/056536A1 |
The present invention relates to alkanoic acids and their derivatives which exhibit activity against PPARs, and hence can be used as antidiabetic compounds. Compounds disclosed herein can be used as peroxisome proliferation activated rec...
|
|
WO/2005/054871A2 |
Embodiments of this invention relate to the analysis of mass spectral data in the quiet zones.
|
|
WO/2005/054217A1 |
A phenothiazinium compound of Formula (I) for use as an antimicrobial agent for the prevention of microbial infections wherein: Rl, R2, R3 and R4 each independently is an optionally substituted linear, branched or cyclic hydrocarbon grou...
|
|
WO/2005/051932A1 |
Arylheterocycle derivatives which are represented by the formula (1): (1) wherein R1 represents C1-6 alkyl, etc.; R2 represents halogeno, etc.; m is an integer of 0 to 4; and T represents a group represented by the formula (2), (3), or (...
|
|
WO/2005/049561A2 |
Methods for the preparation of 7-(dipropylamino)pheno-thiazin-3-ylidene]-dipropylamine.
|
|
WO/2005/049589A2 |
Disclosed are novel compounds of formula (I), having hypolipidaemic and hypocholesterolemic properties, their tautomeric forms, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acce...
|
|
WO/2005/044201A2 |
The present invention is directed to water-soluble derivatives of 2,6-diisopropylphenol (Propofol). The compounds act as prodrugs of 2,6-diisopropylphenol and metabolize rapidly to Propofol thereby providing an alternative to the water-i...
|
|
WO/2005/040104A1 |
The present invention relates to novel hypolipidemic, antiobesity, hypocholesterolemic and antidiabetic compounds. More particularly, the present invention relates to novel alkyl carboxylic acids of the general formula (I), their stereoi...
|
|
WO/2005/035511A1 |
A pharmaceutically active N-desmethyl levomepromazine (abbreviated NDM LMP) and method of use. NDM LMP has substantially the same therapeutic effects as the parent levomepromazine but is subject to less disposition (e.g. presystemic and ...
|
|
WO/2005/030676A1 |
This invention pertains to methods of [11C]-radiolabelling 'phenothiazine' and 'phenothiazine-like' compounds, which have a pendant group (which is a primary amino group; a cationic primary imino group; a secondary amino group; a cationi...
|
|
WO/2005/026138A1 |
Disclosed are compounds represented by the general formula (I) below or the like, pharmacologically acceptable salts thereof, or solvates thereof. (I) (wherein R2 and R3 may be the same or different and represent C2-C4 alkyls or the like...
|
|
WO/2005/026208A2 |
The present invention provides an isolated GABAB receptor protein comprising at least one GABABR1a subunit and at least one GABABR2a subunit, characterized in that said GABAB receptor has one high affinity agonist binding site and one lo...
|
|
WO/2005/026127A1 |
A medicine having plasminogen activator inhibitor-1 inhibiting activity, comprising as an active ingredient a compound of the general formula: (I) [wherein R1 and R2 are aromatic groups; W is a group selected from among linkage groups W-...
|
|
WO/2005/023765A1 |
The invention provides a method of preparing a compound of formula (2), wherein R1 and R6 are as defined herein, by a catalytic amidation process in the presence of added carbon dioxide. The inventive methods show surprising rate enhance...
|
|
WO/2005/020897A2 |
Provided are small-molecule Trp-p8 modulators, including Trp-p8 agonists and Trp-p8 antagonists, and compositions comprising small-molecule Trp-p8 agonists as well as methods for identifying and characterizing novel small-molecule Trp-p8...
|
